Listed

Eledon Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2020

Filed with the SEC on Aug 14, 2020 and accepted by EDGAR at Aug 13, 2020, 19:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-04-01 to 2020-06-30$832.0kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2020-01-01 to 2020-06-30$2.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-04-01 to 2020-06-30−$2.6mus-gaap:OperatingIncomeLoss
Operating income6 months2020-01-01 to 2020-06-30−$6.0mus-gaap:OperatingIncomeLoss
Net income3 months2020-04-01 to 2020-06-30−$2.6mus-gaap:NetIncomeLoss
Net income6 months2020-01-01 to 2020-06-30−$10.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-04-01 to 2020-06-30−$0.15us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2020-01-01 to 2020-06-30−$0.63us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2020-01-01 to 2020-06-30−$5.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-06-30$8.8mus-gaap:Cash
Current assetsAt period end2020-06-30$9.8mus-gaap:AssetsCurrent
Total assetsAt period end2020-06-30$10.5mus-gaap:Assets
Current liabilitiesAt period end2020-06-30$1.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-06-30$1.1mus-gaap:Liabilities
Shareholders' equityAt period end2020-06-30$9.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-040128. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.